This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Helsinn Healthcare SA

Drug Names(s): R-1124

Description: Netupitant is a potent and selective NK-1 receptor antagonist.

Deal Structure: Netupitant was originally developed by Roche.

Helsinn and Roche
In May 2005, Helsinn healthcare and Roche announced the signing of a licensing agreement, granting Helsinn the worldwide rights for netupitant.

Partners: Roche Holding AG

Netupitant News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug